Arbutus Biopharma Corporation

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Arbutus Biopharma Corporation sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 1 currently recruiting 3 completed early-phase tilt upper quartile by trial count

Arbutus Biopharma Corporation: 7 sponsored US clinical trials, 1 recruiting.

Arbutus Biopharma Corporation sponsors 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Long Term Follow-up, with 1 trials.

Upper-quartile sponsor footprint

Arbutus Biopharma Corporation sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING

Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)

NCT06277037
COMPLETED Phase 2

Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

NCT04980482
COMPLETED Phase 1

Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma

NCT02191878
TERMINATED Phase 1

Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802

NCT02041715
TERMINATED Phase 1

Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion

NCT01518881
COMPLETED Phase 1

A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients

NCT01262235
TERMINATED Phase 1

Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol

NCT00927459

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 1

Therapeutic Areas

Long Term Follow-up 1
NET 1
ACC 1
Adrenocortical Carcinoma 1
Neuroendocrine Tumors 1
Cancer 1

What is open in the Arbutus Biopharma Corporation pipeline

1 recruiting of 7 indexed (14% open); 3 completed (43%).

Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Long Term Follow-up (1 trial), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Arbutus Biopharma Corporation: open-pipeline peers nationwide

Peers matched on 7 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Arbutus Biopharma Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40% Total trials Recruiting share Arbutus Biopharma Corporation3M4Life Research89bioAbbott Diagnostics DivisionAcademic and Community Cancer Research UnitedAdaptive BiotechnologiesAgelessRxAlaska Blind Child Discovery
Arbutus Biopharma Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Arbutus Biopharma Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Arbutus Biopharma Corporation page

7 registered trials is a research-attention snapshot, not an endorsement of Arbutus Biopharma Corporation or any single study.

  • 1 of Arbutus Biopharma Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Long Term Follow-up is the condition Arbutus Biopharma Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Long Term Follow-up trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Arbutus Biopharma Corporation pipeline card: 7 registered trials from official public datasets.Report a data error.